TICKERNOMICS Sign up
Last Update: 2023-12-23 06:00:34
Phathom Pharmaceuticals Inc. ( PHAT ) https://www.phathompharma.com
8.98USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-20.46%
PHAT
SPY
30.72%
-74.73%
PHAT
SPY
112.82%
PHAT
0.00%
SPY
201.04%
PHAT
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
495.14
382.79
0.41
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.67
0.00
-27.86
-29.22
0.00
-2.69
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-104.52
-86.12
0.00
Other Earnings and Cash Flow Stats:
Phathom Pharmaceuticals Inc. ( PHAT ) Net Income TTM ($MM) is -204.02
Phathom Pharmaceuticals Inc. ( PHAT ) Operating Income TTM ($MM) is -154.91
Phathom Pharmaceuticals Inc. ( PHAT ) Owners' Earnings Annual ($MM) is 0.00
Phathom Pharmaceuticals Inc. ( PHAT ) Current Price to Owners' Earnings ratio is 0.00
Phathom Pharmaceuticals Inc. ( PHAT ) EBITDA TTM ($MM) is -152.73
Phathom Pharmaceuticals Inc. ( PHAT ) EBITDA Margin is 0.00%
Capital Allocation:
Phathom Pharmaceuticals Inc. ( PHAT ) has paid 0.00 dividends per share and bought back -17.962113 million shares in the past 12 months
Phathom Pharmaceuticals Inc. ( PHAT ) has increased its debt by 4.834 million USD in the last 12 months
Capital Structure:
Phathom Pharmaceuticals Inc. ( PHAT ) Interest-bearing Debt ($MM) as of last quarter is 101
Phathom Pharmaceuticals Inc. ( PHAT ) Annual Working Capital Investments ($MM) are -127
Phathom Pharmaceuticals Inc. ( PHAT ) Book Value ($MM) as of last quarter is -18
Phathom Pharmaceuticals Inc. ( PHAT ) Debt/Capital as of last quarter is -571%
Other Balance Sheet Stats:
Phathom Pharmaceuticals Inc. ( PHAT ) has 213 million in cash on hand as of last quarter
Phathom Pharmaceuticals Inc. ( PHAT ) has 23 million of liabilities due within 12 months, and long term debt 99 as of last quarter
Phathom Pharmaceuticals Inc. ( PHAT ) has 56 common shares outstanding as of last quarter
Phathom Pharmaceuticals Inc. ( PHAT ) has 0 million USD of preferred stock value
Academic Scores:
Phathom Pharmaceuticals Inc. ( PHAT ) Altman Z-Score is -4.83 as of last quarter
Phathom Pharmaceuticals Inc. ( PHAT ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Phathom Pharmaceuticals Inc. ( PHAT ) largest shareholder is Kennedy Capital Management Inc owning 1061745 shares at 9.53 ($MM) value
Asit Parikh(an insider) Bought 2500 shares of Phathom Pharmaceuticals Inc. ( PHAT ) for the amount of $19500.00 on 2023-11-08
17.18% of Phathom Pharmaceuticals Inc. ( PHAT ) is held by insiders, and 78.00% is held by institutions
Phathom Pharmaceuticals Inc. ( PHAT ) went public on 2019-10-25
Other Phathom Pharmaceuticals Inc. ( PHAT ) financial metrics:
FCF:-148.99
Unlevered Free Cash Flow:0.00
EPS:-3.05
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:973.23
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Phathom Pharmaceuticals Inc. ( PHAT ) :
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.